| Identification | Back Directory | [Name]
[1,4]Oxazepino[2,3-c]quinolin-6(7H)-one, 10-[[5-chloro-2-[(3R,5S)-3-hydroxy-5-methyl-1-piperidinyl]-4-pyrimidinyl]amino]-2-cyclopropyl-3,3-difluoro-1,2,3,4-tetrahydro-7-methyl-, (2S)- | [CAS]
2378853-66-6 | [Synonyms]
CCT373566
[1,4]Oxazepino[2,3-c]quinolin-6(7H)-one, 10-[[5-chloro-2-[(3R,5S)-3-hydroxy-5-methyl-1-piperidinyl]-4-pyrimidinyl]amino]-2-cyclopropyl-3,3-difluoro-1,2,3,4-tetrahydro-7-methyl-, (2S)- | [Molecular Formula]
C26H29ClF2N6O3 | [MOL File]
2378853-66-6.mol | [Molecular Weight]
547 |
| Chemical Properties | Back Directory | [Boiling point ]
704.8±70.0 °C(Predicted) | [density ]
1.50±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
14.34±0.40(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Description]
CCT373566 is a highly potent BCL6 degrader (IC50 =0.7 nM) suitable for sustained depletion of BCL6 in vivo. CCT373566 showed modest in vivo efficacy in a lymphoma xenograft mouse model following oral dosing. The transcriptional repressor BCL6 is an oncogenic driver found to be deregulated in lymphoid malignancies. | [Uses]
CCT373566 is a potent and orally active molecular glue degrader of transcriptional repressor BCL6, with an IC50 of 2.2 nM. CCT373566 shows strong antiproliferative efficacy in vitro and reduction in tumor growth in vivo[1]. | [in vitro]
The antiproliferative activity of the degrader CCT373566 and the inhibitor CCT373567 was tested in a panel of cell lines (Table 5). The degradation of BCL6 by CCT373566 translated into potent antiproliferative activity._x000D_
_x000D_
Reference: J Med Chem. 2022 Jun 23;65(12):8191-8207. https://pubmed.ncbi.nlm.nih.gov/35653645/ | [target]
CCT373566 is a potent and orally active degrader of transcriptional repressor BCL6, with an IC50 of 2.2 nM. | [References]
[1] Huckvale R, et, al. Improved Binding Affinity and Pharmacokinetics Enable Sustained Degradation of BCL6 In Vivo. J Med Chem. 2022 Jun 23;65(12):8191-8207. DOI:10.1021/acs.jmedchem.1c02175 |
|
|